Heron Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Heron Therapeutics, Inc. (Nasdaq: HRTX) is a commercial-stage biotechnology company that develops and commercializes therapies to advance the standard of care for acute care and oncology patients through its proprietary Biochronomer drug delivery technology. The company offers ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and low-dose meloxicam for postoperative pain management in adults undergoing small- to medium-open surgical procedures via a single administration; APONVIE, an intravenous aprepitant injection indicated for preventing postoperative nausea and vomiting (PONV) in adults; CINVANTI, an intravenous fosaprepitant for chemotherapy-induced nausea and vomiting (CINV) approved as both a 30-minute infusion and a 2-minute injection; and SUSTOL, a subcutaneous extended-release granisetron injection utilizing Biochronomer technology to maintain therapeutic levels for at least five days for CINV prevention in adults receiving moderately emetogenic chemotherapy or anthracycline plus cyclophosphamide regimens. Heron Therapeutics primarily serves U.S. healthcare providers including surgeons, oncologists, nurses, and pharmacists through a targeted sales force and specialty distributors, with products registered in over 30 foreign countries spanning Europe, Asia-Pacific, and Latin America though commercial focus remains domestic. Founded in 1983 and headquartered in Cary, North Carolina following relocation from San Diego, California, the company recently completed a comprehensive capital restructuring in 2025 that reduced total debt from $175 million to $145 million, secured a senior credit facility of up to $150 million from Hercules Capital due in 2030 with $110 million committed at closing and additional tranches tied to milestones, launched dedicated sales teams for ZYNRELEF and APONVIE in Q3 2025 to drive adoption, transitioned ZYNRELEF to a Vial Access Needle optimizing hospital and ambulatory surgical center preparation, obtained a permanent CMS J-code for ZYNRELEF effective October 1, 2025 to enhance reimbursement, and appointed Brett Fleshman as Chief Business Officer in August 2024 and Thomas Cusack to its board in October 2025.
Company News
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
Heron Therapeutics Q2 Earnings Call Highlights
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
New Strong Sell Stocks for July 15th
U.S. District Court Issues Decision Regarding CINVANTI® Patents
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics Q1 Earnings Call Highlights
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
Heron: Near The Bottom Of A Trading Range Despite Positives
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX